A Comparative Follow-up Study of Metabolic Syndrome in Schizophrenia Patients Treated with Olanzapine and Risperidone

Background: Schizophrenia is a severe mental illness characterized by anomalies in thought processes, perceptions, emotional response, and social relations. It affects approximately 1% of the global population, translating to millions of individuals suffering from its debilitating effects. Metabolic syndrome refers to a cluster of interrelated risk factors that significantly elevate the risk of cardiovascular diseases and type 2 diabetes. Individuals with schizophrenia are more likely to suffer physical ailments, notably cardiovascular problems. The interplay between the chronic nature of schizophrenia and physical health is multifactorial, involving genetic predisposition, lifestyle factors, and treatment-related side effects. Second-generation antipsychotics (SGAs), including olanzapine and risperidone, have revolutionized the treatment of schizophrenia by targeting both positive symptoms (e.g., delusions, hallucinations) and negative symptoms (e.g., reduced emotional expression, social withdrawal). Their use is associated with an increased risk of metabolic side effects, including weight gain, dyslipidemia, and insulin resistance, which contribute to the development of metabolic syndrome Methodology: This comparative observational study analyzed the metabolic impact of olanzapine (n=70) versus risperidone (n=70) over one year in 140 schizophrenia patients aged 18–50 at the Government Hospital for Mental Care, Visakhapatnam. Participants, selected by simple random sampling and meeting ICD-11 criteria, were either drug-naïve or had a six-month washout period, excluding those with pre-existing metabolic conditions. Researchers measured BMI, waist circumference, blood pressure, and lipid profiles at baseline, three, and six months, diagnosing metabolic syndrome via IDF and NCEP ATP III criteria, with 121 participants completing the six-month follow-up (58 in the olanzapine group, 63 in the risperidone group). Results: This prospective study provides valuable evidence that olanzapine is associated with significantly higher metabolic risk compared to risperidone, as demonstrated by greater changes in weight, BMI, waist circumference, triglycerides, HDL cholesterol, and incidence of metabolic syndrome over a 6-month period. Independent risk factors included high baseline BMI, physical inactivity, poor diet, and family history of cardiometabolic disease. Conclusion: In conclusion, this study provides robust evidence supporting the metabolic safety advantages of risperidone over olanzapine. The findings align with both Indian and global literature and advocate for routine risk stratification and tailored therapeutic approaches in schizophrenia care. Given the rising burden of antipsychotic-induced metabolic syndrome, integrating physical health surveillance into psychiatric practice is not only advisable but essential for long-term patient well-being.